Association between kaolin-induced maximum amplitude and slow-flow/no-reflow in ST elevation myocardial infarction

Related Experiment Video

Updated: Sep 1, 2025

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

Qing Li1, Enmin Xie2, Yimin Tu2

  • 1Department of Cardiology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China; Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China.

International Journal of Cardiology
|August 15, 2022
PubMed

Insights

Maximum amplitude during thrombin activation (MAthrombin) predicts slow-flow/no-reflow in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention. Higher MAthrombin levels are linked to increased risk of adverse cardiovascular events.

Area of Science:

  • Cardiology
  • Hematology
  • Interventional Cardiology

Background:

  • High thrombus burden in ST-segment elevation myocardial infarction (STEMI) increases slow-flow/no-reflow risk.
  • The association between kaolin-induced maximum amplitude (MAthrombin) and slow-flow/no-reflow remains underexplored.

Purpose of the Study:

  • To investigate the predictive value of MAthrombin for slow-flow/no-reflow in STEMI patients.
  • To assess MAthrombin as a risk factor for long-term adverse cardiovascular events.

Main Methods:

  • Retrospective enrollment of 690 STEMI patients undergoing primary percutaneous coronary intervention (PCI).
  • MAthrombin measurement via thromboelastography before PCI.
  • Analysis using logistic regression and restricted cubic spline regression (RCS).
  • Follow-up for adverse cardiovascular events.

Main Results:

  • MAthrombin was an independent risk factor for slow-flow/no-reflow (TIMI flow grade ≤2).
  • RCS revealed a nonlinear relationship between MAthrombin and slow-flow/no-reflow.
  • A MAthrombin cutoff of 68 mm predicted slow-flow/no-reflow.
  • Elevated MAthrombin and slow-flow/no-reflow independently predicted long-term adverse cardiovascular events.

Conclusions:

  • MAthrombin is a significant independent risk factor for predicting slow-flow/no-reflow in STEMI patients post-primary PCI.
  • MAthrombin may serve as a valuable biomarker for risk stratification in STEMI management.
Abstract

Keywords:
Cardiovascular eventsKaolin-induced maximum amplitudeST segment elevation myocardial infarctionSlow-flow/ no-reflow

More Related Videos

Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice05:07

Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice

Published on: August 25, 2023

1.2K
Myocardial Infarction and Functional Outcome Assessment in Pigs12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.1K

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
67
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
40
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
140
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
23